Pyrido[3,4-b]pyrazin-2(1H)-one, 3-[4-(2-hydroxyethyl)-1-piperazinyl]-7-(6-Methoxy-3-pyridinyl)-1-(2-propoxyethyl) manufacturers
- PF-03049423
-
- $79.00
-
2026-07-14
- CAS:954138-07-9
- Purity: 99.93%
- Supply Ability: 10g
|
| | Pyrido[3,4-b]pyrazin-2(1H)-one, 3-[4-(2-hydroxyethyl)-1-piperazinyl]-7-(6-Methoxy-3-pyridinyl)-1-(2-propoxyethyl) Basic information |
| | Pyrido[3,4-b]pyrazin-2(1H)-one, 3-[4-(2-hydroxyethyl)-1-piperazinyl]-7-(6-Methoxy-3-pyridinyl)-1-(2-propoxyethyl) Chemical Properties |
| | Pyrido[3,4-b]pyrazin-2(1H)-one, 3-[4-(2-hydroxyethyl)-1-piperazinyl]-7-(6-Methoxy-3-pyridinyl)-1-(2-propoxyethyl) Usage And Synthesis |
| Uses | PF-03049423 (Compound PF-5) free base is a potent and highly selective phosphodiesterase-5A inhibitor with an IC50 of about 0.2 nM for rat and human platelet enzyme. PF-03049423 free base can be used for the research of acute ischaemic stroke[1]. | | in vivo | PF-03049423 (Compound PF-5) (1-10 mg/kg; s.c.; b.i.d. for 7 days) promotes functional recovery in a rat model of severe stroke induced by permanent middle cerebral artery occlusion[1].
PF-03049423 (1.0 mg/kg b.i.d. or 0.6 mg/kg q.d. for 7 days) improves poststroke sensory–motor behavioral outcome even when the treatment is initiated 24-72 hours after occlusion[1]. | Animal Model: | Male Sprague-Dawley rats, middle cerebral artery occlusion (MCA-o) model[1] | | Dosage: | 0.1, 1, or 10 mg/kg | | Administration: | Subcutaneous injection, b.i.d. for 7 days | | Result: | Improved functional recovery at 1 mg/kg and 10 mg/kg. |
| | IC 50 | PDE5A; rat and human platelet enzyme: ~0.2 nM (IC50) | | References | [1] Menniti FS, et al. Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism. J Pharmacol Exp Ther. 2009 Dec;331(3):842-50. DOI:10.1124/jpet.109.156919 |
| | Pyrido[3,4-b]pyrazin-2(1H)-one, 3-[4-(2-hydroxyethyl)-1-piperazinyl]-7-(6-Methoxy-3-pyridinyl)-1-(2-propoxyethyl) Preparation Products And Raw materials |
|